The date format must match "dd.mm.YYYY"
Longer survival is offset by more frequent – and partly severe – side effects and deterioration in symptoms and quality of life. Overall, an added benefit is not proven.
Given in addition to statin therapy, ezetimibe has a preventive effect in patients with CHD and acute coronary syndrome.
In the British Medical Journal, IQWiG researchers analyse the first 216 AMNOG assessments of new drugs and derive proposals for more targeted drug development.
For other important outcomes, studies are less informative, the correlation is unclear or data are missing. IQWiG presents the first of overall 8 reports on evidence for minimum volumes.
The additional application of the new treatment method prolongs survival, as a recent study shows. However, it can also be burdensome for patients.
New analyses in an addendum confirm hint of an added benefit in one of four research questions. Especially with regard to quality of life, usable data are now available.
In two weeks' time, the 16th HTAi Annual Meeting will start in Cologne: globalization and digitalization also call for adequate methods and effective action in health technology assessment. IQWiG is actively involved.
Meaningful studies are lacking for certain patient groups. Disease-specific registries could help close the data gap.
There are advantages in overall survival, which are not offset by any disadvantages of similar importance. Extent of the added benefit depends on the patient risk scores.
Data are lacking for arguments on the pros and cons, as the available studies examine the outpatient sector. IQWiG proposes a design for a new study.
Symptomatic progression is significantly retarded by this drug. This advantage clearly outweighs the disadvantages presented by some side effects.
In the Journal of Clinical Epidemiology, an international team of authors discusses the possibilities and limitations of graphical representations of statements on absolute effects.
Study indicates longer overall survival of postmenopausal women. However, there is a higher frequency of severe diseases of blood and lymphatic system. Overall, added benefit not proven.
Hint and indication of benefit for primary and secondary wound healing, respectively. But studies still concealed. Comments on preliminary report “primary wound healing” possible until 29.4.
Informative studies are still lacking for the comparison with the currently used risk-based strategy.
The first drug of a new drug class can reduce the number of headache days if other prophylactic medications have failed or have not been an option.
Commissioned by the Federal Ministry of Health, the Institute searched for studies on vaginal (“natural”) birth and assessed them. The guideline group appreciates the high quality of the reports.
Only few study participants received approval-compliant treatment. Therefore, the extent of added benefit is non-quantifiable.
The focus is on international HTA activities. Further topics: 7 years of AMNOG, big data, studies on medical devices, and other topics. Available online at IQWiG as a PDF or as a print version.
This combination showed advantages in survival and recurrence. An added benefit was not proven for another combination used in advanced disease.
+49 221 35685-151
+49 221 35685-158
To save your search result, please copy the link below and paste it into a new tab/window.